Response to the Letter to the Editor: "Recalibrating Low-Dose Computed Tomography Lung Cancer Screening: Overdiagnosis, Access, and Equity" [0.03%]
关于《致编辑信件：“重新校准低剂量CT肺癌筛查：过度诊断、可及性和公平性”》的回复
Dongchen Xie,Wanghong Xu
Dongchen Xie
Recalibrating Low-Dose Computed Tomography Lung Cancer Screening: Overdiagnosis, Access, and Equity [0.03%]
低剂量螺旋CT肺癌筛查的再评估：过度诊断、可及性和公平性
Bi-Yu Gao,Yuan-Ti Lee
Bi-Yu Gao
"WEE"ding Out Resistance to Osimertinib in the "ARID"1A-Mutated Badlands [0.03%]
"WEEDING OUT"在"ARID"1A突变情况下的奥希替尼耐药问题
Steven G Gray,Luciano Mutti
Steven G Gray
Reading Between the Lines: Circulating Tumor DNA Dynamics Illuminate Immunotherapy Outcomes in Lung Squamous Cell Carcinoma [0.03%]
解读免疫治疗效果的潜在标志物：液体活检指导下的非小细胞肺癌免疫治疗研究进展
Eloísa Jantus-Lewintre,Ana Patiño-García,Angel Díaz-Lagares
Eloísa Jantus-Lewintre
Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors or Blocking Antibodies? Unraveling Vascular Endothelial Growth Factor Inhibition Strategies [0.03%]
血管内皮生长因子酪氨酸激酶抑制剂还是阻断性单克隆抗体？揭秘血管内皮生长因子抑制策略
Daphne W Dumoulin,G Joachim V Aerts
Daphne W Dumoulin
A Grading System for Resected Invasive Squamous Cell Carcinoma of the Lung: A Multi-Institutional Study by the IASLC Pathology Committee [0.03%]
一项多机构研究：肺癌侵袭性鳞状细胞癌切除术后的分级系统（由国际肺癌研究协会病理委员会提出）
Mari Mino-Kenudson,Sabina Berezowska,Yuko Minami et al.
Mari Mino-Kenudson et al.
Background: Tumor grading informs therapy and patient management across many organs; yet no consensus exists for grading invasive squamous cell carcinoma of the lung (LUSC). This study aimed to develop a globally applicab...
Corrigendum to 'Neoadjuvant Chemoimmunotherapy Complicates Subsequent Surgical Resection and Adjuvant Immunotherapy Is Preferable From the Surgical Standpoint' [Journal of Thoracic Oncology Volume 19 Issue 6 (2024) 858-861] [0.03%]
关于“新辅助化疗免疫治疗复杂化随后的手术切除，从外科角度来看辅助免疫治疗更为可取”一文的勘误[J Thorac OncolVolume 19Issue 6(2024)858-861]
Paula Ugalde Figueroa,Valérie Lacroix,Paul E Van Schil
Paula Ugalde Figueroa
International Thymic Malignancy Interest Group Standard Definitions, Policies, and Reporting Measures for Thymic Epithelial Tumors [0.03%]
国际胸腺恶性肿瘤研究组关于胸腺上皮性肿瘤的标准定义、政策和报告措施
Wentao Fang,Frank Detterbeck,Jeanne B Ackman et al.
Wentao Fang et al.
Thymic epithelial tumors are rare diseases, with frequently indolent nature. A common language is essential for accurate communication in clinical management and research for this disease. The International Thymic Malignancy Interest Group ...
Kimberly A Shoenbill,Jamie S Ostroff,Kathryn L Taylor et al.
Kimberly A Shoenbill et al.
Introduction: Although there is widespread acceptance of the importance of assessing and treating tobacco use in cancer care settings, there is much variation in the documentation and reporting of metrics relevant to toba...
Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers with Different MET Exon 14 Skipping Mutations [0.03%]
简报：基于DNA的测序在区分具有不同MET外显子14跳跃突变的不同原发性肺癌中的关键作用
Federica Pecci,Prashasti Agrawal,Jessica S Ross et al.
Federica Pecci et al.
Background: MET exon 14 skipping (METex14) mutations are found in 3-4% of non-small cell lung cancer (NSCLC) and can be detected through DNA- and/or RNA-based sequencing assays. Whereas RNA sequencing simply reports skipp...